Multiple Myeloma and Other Plasma Cell Neoplasms

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Multiple Myeloma and Other Plasma Cell Neoplasms by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319255866
Publisher: Springer International Publishing Publication: February 16, 2018
Imprint: Springer Language: English
Author:
ISBN: 9783319255866
Publisher: Springer International Publishing
Publication: February 16, 2018
Imprint: Springer
Language: English

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

More books from Springer International Publishing

Cover of the book Advanced Technologies for Intelligent Transportation Systems by
Cover of the book Assistive Technologies for the Interaction of the Elderly by
Cover of the book Law, Politics and the Limits of Prosecuting Mass Atrocity by
Cover of the book System Engineering Approach to Planning Anticancer Therapies by
Cover of the book Seaports in International Law by
Cover of the book Heidegger and the Death of God by
Cover of the book The Law of Nations and Britain’s Quest for Naval Security by
Cover of the book The Creation of Local Innovation Systems in Emerging Countries by
Cover of the book Automated Deduction - CADE-25 by
Cover of the book Peptides and Peptide-based Biomaterials and their Biomedical Applications by
Cover of the book Color-Induced Graph Colorings by
Cover of the book Six-Phase Electric Machines by
Cover of the book Practical Wisdom and Democratic Education by
Cover of the book Image Analysis and Recognition by
Cover of the book When China Goes to the Moon... by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy